| Literature DB >> 28851359 |
Annelies Michiels1, Ioannis Arsenakis2, Filip Boyen3, Roman Krejci4, Freddy Haesebrouck3, Dominiek Maes2.
Abstract
BACKGROUND: Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary agent of enzootic pneumonia in pigs. Pigs are often infected with different M. hyopneumoniae strains. This study assessed the efficacy of vaccination against experimental infection with two genetically different M. hyopneumoniae strains in weaned piglets. At 33 days of age (D0), 45 M. hyopneumoniae-free piglets were randomly assigned to three different groups: 1) negative control group (NCG; n = 5): not vaccinated, not infected, 2) positive control group (PCG; n = 20): not vaccinated, infected, and 3) vaccination group (VG; n = 20): single vaccination with an inactivated whole-cell M. hyopneumoniae vaccine (Hyogen®, Ceva) (D1), infected. The PCG and VG were endotracheally inoculated with 7 × 107 CCU in 7 ml of the highly virulent M. hyopneumoniae strain F7.2C (D24) and 7 × 107 CCU in 7 ml low virulent strain F1.12A (D25). A respiratory disease score (RDS) was assessed from D24 until D53. At D53 (euthanasia), macroscopic lung lesions (MLL) were scored, log copies of M. hyopneumoniae DNA (qPCR) and IL-1 and IL-6-concentrations (ELISA) on bronchoalveolar lavage fluid were determined.Entities:
Keywords: Double challenge; Mycoplasma hyopneumoniae; Vaccination
Mesh:
Substances:
Year: 2017 PMID: 28851359 PMCID: PMC5576127 DOI: 10.1186/s12917-017-1195-0
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Results of different parameters in the different experimental groups
| Parameter | Experimental Groups | |||
|---|---|---|---|---|
| NCG (# = 5) | PCG (# = 20) | VG (# = 20) |
| |
| RDS | ||||
| D1–53 | 0 ± 0 a | 0.68 ± 0.41b | 0.32 ± 0.86 c |
|
| D1–23 | 0 ± 0 a | 0 ± 0 a | 0.017 ± 0.060 a | 0.983 |
| D24–53 | 0 ± 0 a | 1.20 ± 0.83 b | 0.55 ± 0.42 c |
|
| Weight ± SD | ||||
| D0 | 7.04 ± 1.22a | 6.97 ± 0.84 a | 7.04 ± 1.02 a | 0.966 |
| D24 | 15.25 ± 3.96 a | 16.39 ± 2.16 a | 15.61 ± 2.96 a | 0.581 |
| D53 | 36.51 ± 8.63 a | 34.63 ± 6.63 a | 34.27 ± 5.35 a | 0.808 |
| ADG (g/pig/d) | ||||
| D0–24 | 357 ± 123 a | 393 ± 62.8 a | 357 ± 92.0 a | 0.372 |
| D24–53 | 733 ± 194 a | 629 ± 199 a | 643 ± 102 a | 0.504 |
| D0–53 | 563 ± 144 a | 522 ± 121 a | 514 ± 87.0 a | 0.714 |
| MLL, histopathology and air analysis D53 | ||||
| MLL | 0 ± 0 a | 7.56 ± 4.73 b | 0.68 ± 0.73 a |
|
| Histopathology | 1.31 ± 0.18 a | 3.32 ± 0.85 b | 1.92 ± 0.47 c |
|
| Percentage of air (%) | 47.72 ± 7.29 a | 34.49 ± 8.22 b | 45.23 ± 5.99 a |
|
| log copies of | ||||
| D39 | 0.36 ± 0.64 a | 1.81 ± 1.32 a | 1.23 ± 1.61 a | 0.062 |
| D53 | 0.40 ± 0.43 a | 3.99 ± 1.20 b | 1.78 ± 1.36 a |
|
| Percentage of | ||||
| D39 | (0/4) 0a | (14/20) 70b | (7/20) 35c |
|
| D53 | (0/4) 0a | (19/20) 95b | (12/20) 60c |
|
|
| ||||
| D1 | 1.51 ± 0.037 a | 1.48 ± 0.058 a | 1.48 ± 0.16 a | 0.578 |
| D24 | 0.91 ± 0.044 a | 0.95 ± 0.069 a | 0.50 ± 0.17 b |
|
| D53 | 0.90 ± 0.10 a | 0.23 ± 0.11 a | 0.087 ± 0.041 b |
|
| Percentage of ELISA | ||||
| D1 | (0/5) 0a | (0/20) 0a | (0/20) 0a | 1.000 |
| D24 | (0/4) 0a | (0/20) 0a | (15/20) 75b |
|
| D53 | (0/4) 0a | (20/20) 100b | (20/20)100b |
|
The respiratory disease score (RDS), body weight, average daily gain (ADG), M. hyopneumoniae specific antibodies, macroscopical lung lesions (MLL), histopathology and air analysis, log copies of M. hyopneumoniae DNA (qPCR), percentage of of M. hyopneumoniae qPCR positive samples, M. hyopneumoniae specific AB expressed in OD-values and Percentage of ELISA M. hyopneumoniae positive samples
a,b,cDifferent superscripts in one row are statistically different (P < 0.05)
NCG negative control group, PCG positive control group, VG vaccination group, SD standard deviation, D Day of the study, ADG average daily gain, kg kilogram, RDS respiratory disease score, M. hyopneumoniae Mycoplasma hyopneumoniae, AB antibodies, OD optical densities, # number, MLL macroscopic lung lesions, qPCR quantitative polymerase chain reaction, DNA DeoxyriboNucleic Acid, BALF bronchoalveolar lavage fluid
Fig. 1Average respiratory disease score (RDS) during the trial for the negative control group (NCG), positive control group (PCG) and vaccination group (VG). The average RDS was assessed daily from day 1 until day 53. The piglets were vaccinated at D1 and the inoculations were performed at D24 and D25
Immunological parameters measured in the BALF at D39 and D53
| Parameter | Experimental groups | |||
|---|---|---|---|---|
| NCG (# = 5) | PCG (# = 20) | VG (# = 20) |
| |
| Ig G ± SD (OD-values) | ||||
| D39 | 0 ± 0 a | 0.069 ± 0.14 a | 0.31 ± 0.65 a | 0.366 |
| D53 | 0.38 ± 0.17 a | 2.25 ± 0.91 b | 2.41 ± 0.88 b |
|
| Ig A ± SD (OD-values) | ||||
| D39 | 0 ± 0 a | 0.067 ± 0.18 a | 0.55 ± 0.99 a | 0.359 |
| D53 | 0.18 ± 0.14 a | 2.10 ± 0.75 b | 2.08 ± 0.58 b |
|
| TNF-α ± SD (pg/ml) | ||||
| D39 | 23.61 ± 1.74 a | 18.56 ± 4.40 a | 21.12 ± 4.56a |
|
| D53 | 16.03 ± 1.10 a | 14.53 ± 5.95 a | 15.15 ± 2.40a | 0.065 |
| IL-1 ± SD (pg/ml) | ||||
| D39 | 32.47 ± 1.77 a | 239.63 ± 511.35 a | 247.13 ± 606.71a | 0.367 |
| D53 | 17.61 ± 1.98 a | 1283.39 ± 1075.65 b | 53.04 ± 54.23 a |
|
| IL-6 ± SD (pg/ml) | ||||
| D39 | 130.33 ± 18.65 ab | 242.24 ± 122.23 a | 164.64 ± 84.48 b | 0.03 |
| D53 | 148.10 ± 8.89 a | 493.35 ± 494.70 b | 259.80 ± 333.38 a |
|
D39: two weeks after challenge
D53: necropsy
a,bDifferent superscripts in one row are statistically different (P < 0.05)
NCG negative control group, PCG positive control group, VG vaccination group, SD standard deviation, D Day of the study, OD optical densities, # number